Rapport Therapeutics Inc.... (RAPP)
Rapport Therapeutics Common Stock Statistics
Share Statistics
Rapport Therapeutics Common Stock has 36.5M shares outstanding. The number of shares has increased by 3.17% in one year.
| Shares Outstanding | 36.5M |
| Shares Change (YoY) | 3.17% |
| Shares Change (QoQ) | -0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.41M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 1.5M, so 4.1% of the outstanding shares have been sold short.
| Short Interest | 1.5M |
| Short % of Shares Out | 4.1% |
| Short % of Float | 8.58% |
| Short Ratio (days to cover) | 12.33 |
Valuation Ratios
The PE ratio is -46.98 and the forward PE ratio is -3.91. Rapport Therapeutics Common Stock's PEG ratio is -0.47.
| PE Ratio | -46.98 |
| Forward PE | -3.91 |
| PS Ratio | 0 |
| Forward PS | 13.3 |
| PB Ratio | 12.05 |
| P/FCF Ratio | -54.72 |
| PEG Ratio | -0.47 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rapport Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.34, with a Debt / Equity ratio of 0.
| Current Ratio | 35.34 |
| Quick Ratio | 35.34 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.13M |
| Employee Count | 69 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.35, so Rapport Therapeutics Common Stock's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 11.79 |
| 200-Day Moving Average | 18.76 |
| Relative Strength Index (RSI) | 42.43 |
| Average Volume (20 Days) | 228.24K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -83.06M |
| Net Income | -78.31M |
| EBITDA | -83.06M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.38 |
Balance Sheet
The company has 56.8M in cash and 1.48M in debt, giving a net cash position of 55.33M.
| Cash & Cash Equivalents | 56.8M |
| Total Debt | 1.48M |
| Net Cash | 55.33M |
| Retained Earnings | -123.75M |
| Total Assets | 314.93M |
| Working Capital | 301.04M |
Cash Flow
In the last 12 months, operating cash flow was -64.83M and capital expenditures -2.4M, giving a free cash flow of -67.23M.
| Operating Cash Flow | -64.83M |
| Capital Expenditures | -2.4M |
| Free Cash Flow | -67.23M |
| FCF Per Share | -0.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RAPP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RAPP is $35, which is 289.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 289.3% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 20.53 |
| Piotroski F-Score | 2 |